Patents
Literature
5 results about "Diastolic function" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In clinical cardiology the term "diastolic function" is most commonly referred as how the heart fills. Parallel to "diastolic function", the term "systolic function" is usually referenced in terms of the left ventricular ejection fraction (LVEF), which is the ratio of stroke volume and end-diastolic volume. Due to the epidemic of heart failure, particularly the cases determined as diastolic heart failure, it is increasingly urgent and crucial to understand the meaning of “diastolic function”. Unlike "systolic function" which can be simply evaluated by LVEF, there are no established dimensionless parameter for "diastolic function" assessment. Hence to further study "diastolic function" the complicated and speculative physiology must be taken into consideration.
Quinazoline dione compounds and their uses
ActiveJP2026516306AOrganic active ingredientsOrganic chemistryHypertrophic cardiomyopathyMarfan syndrome
Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.
Owner:EDGEWISE THERAPEUTICS INC
Use of a gcn2 kinase inhibitor in the manufacture of a medicament for treating heart failure with preserved ejection fraction
The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.
Owner:UNIV OF CHINESE ACAD OF SCI
Quinazolindione compounds and their uses
PendingJP2026086766AOrganic active ingredientsOrganic chemistryHypertrophic cardiomyopathyMarfan syndrome
Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.
Owner:EDGEWISE THERAPEUTICS INC
Use of apolipoprotein m in the preparation of a medicament for treating heart failure with preserved ejection fraction
This invention discloses the application of apolipoprotein M in the preparation of a medicament for treating heart failure with preserved ejection fraction (HFpEF). The medicament comprises apolipoprotein M and a medically acceptable carrier or excipient. Animal experiments have shown that liver-specific overexpression of ApoM improves diastolic dysfunction, myocardial hypertrophy, and myocardial fibrosis in HFpEF mice, while liver-specific knockdown of ApoM exacerbates this pathological process. This provides a novel treatment strategy for HFpEF and also offers a theoretical basis for ApoM as a biomarker for HFpEF.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Use of bckdk gene as a target in preparation of a drug for preventing or treating obesity-related cardiomyopathy
The application discloses application of BCKDK gene as a target point in preparation of a medicine for preventing or treating obesity-related cardiomyopathy. The application firstly determines an important function of BCKDK in obesity-related cardiomyopathy, and overexpression of the BCKDK gene can protect the heart. The application also provides application of a nucleic acid molecule coding BCKDK, an expression vector or a delivery system containing the same, and application of BCKDK or the nucleic acid molecule coding BCKDK as a drug target. Preferably, the drug adopts an adeno-associated virus vector driven by a myocardium-specific promoter, carries a coding sequence of BCKDK or a functional variant, a truncated body or a functional fragment of BCKDK, and realizes myocardium-specific expression. Experiments prove that overexpression of BCKDK can significantly improve myocardial hypertrophy, fibrosis and diastolic dysfunction.
Owner:SOUTHEAST UNIV